Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 16/20 | 0.46 |
| ▸ | TPO | P07202 | 1/20 | 0.46 |
| ▸ | EPX | P11678 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19282206 | 0.89 | MPO (0.49) | MPOTPOEPX | |
| SCHEMBL19282248 | 0.88 | MPO (0.61) | MPOTPOEPXNPC1NFKB1 | |
| SCHEMBL19282300 | 0.86 | MPO (0.40) | MPOTPOEPX | |
| SCHEMBL17594905 | 0.85 | MPO (0.61) | MPOTPOEPXSMN1; SMN2ALDH1A1 | |
| SCHEMBL19282324 | 0.85 | MPO (0.38) | MPOTPOEPX | |
| SCHEMBL19282199 | 0.84 | MPO (0.49) | MPOTPOEPX | |
| SCHEMBL19282337 | 0.83 | RAB9A (0.55) | MPOTPOEPXNPC1NFKB1 | |
| SCHEMBL19282354 | 0.81 | MPO (0.60) | MPOTPOEPX | |
| SCHEMBL19294221 | 0.81 | NPC1 (0.50) | MPOTPOEPXNPC1RAB9A | |
| SCHEMBL19282239 | 0.81 | MPO (0.47) | MPOTPOEPX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10981879-B2 | Thioether triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-04-20 | — | — | US | claimed |
| EP-3191486-B1 | THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRMIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL MYERS SQUIBB CO (US) | 2018-08-01 | — | — | EP | claimed |
| US-10981879-B2 | Thioether triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-04-20 | — | — | US | disclosed |
| US-10981879-B2 | Thioether triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-04-20 | — | — | US | disclosed |
| US-20190031623-A1 | THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL MYERS SQUIBB CO (US) | 2019-01-31 | — | — | US | disclosed |
| US-20190031623-A1 | THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL MYERS SQUIBB CO (US) | 2019-01-31 | — | — | US | disclosed |
| EP-3191486-B1 | THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRMIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL MYERS SQUIBB CO (US) | 2018-08-01 | — | — | EP | disclosed |
| US-20170247343-A1 | THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170247343-A1 | THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170247343-A1 | THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-31 | — | — | US | disclosed |
| EP-3191486-A1 | THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRMIDINE INHIBITORS OF MYELOPEROXIDASE | Bristol-Myers Squibb Company (US) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016040419-A1 | THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRMIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031623-A1 | THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE | EPX, MPO, SERPINB1 | MPO 2/4885TPO 6/4885EPX 1/4885 |
| US-20170247343-A1 | THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE | EPX, MPO, SERPINB1 | MPO 2/4885TPO 6/4885EPX 1/4885 |
| US-10981879-B2 | Thioether triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase | EPX, MPO, SERPINB1 | MPO 2/4885TPO 6/4885EPX 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.